EXTENDED REPORT

¹ Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA
² Shiley Eye Center, University of California, San Diego, San Diego, CA, USA
³ Charlotte Eye Ear Nose and Throat Associates, Charlotte, NC, USA
⁴ Department of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA
⁵ Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA

Correspondence to:
Correspondence to:
David G Hwang, MD, Cornea and Refractive Surgery Service, Department of Ophthalmology, University of California, San Francisco School of Medicine, 10 Koret Way, San Francisco, CA 94143–0730, USA;
dghwang{at}itsa.ucsf.edu

Aim: To compare the efficacy and safety of levofloxacin 0.5% ophthalmic solution (Quixin) with placebo for treatment of bacterial conjunctivitis.

Methods: In this prospective, randomised, placebo controlled, double masked, multicentre study, 249 patients with bacterial conjunctivitis received either 0.5% levofloxacin (n = 126) or placebo (n = 123) for 5 days, administered every 2 hours on days 1–2, then every 4 hours on days 3–5. Cultures were obtained and signs/symptoms evaluated at baseline, interim, and final visits. The end point was the last evaluable observation. Primary microbial outcomes were based on culture results; clinical outcomes were based on resolution of cardinal signs.

Results: 117 patients (60 levofloxacin, 57 placebo) were evaluated. Microbial eradication rates were significantly greater with levofloxacin at all time points, reaching 90% at end point. In a subgroup analysis, differences in eradication rates at end point were most pronounced in children but were also statistically significant for levofloxacin in adults. Clinical cure rates were significantly greater with levofloxacin at final visit and end point. Statistically significant differences favouring levofloxacin were measured at end point for resolution of conjunctival discharge, bulbar conjunctival injection, palpebral conjunctival injection, burning/stinging, itching, and photophobia. Adverse events were similar between groups. Safety composite scores analysed by age indicated significantly fewer children on levofloxacin experienced worsening symptoms.

Conclusions: Levofloxacin 0.5% ophthalmic solution is safe and effective for treatment of bacterial conjunctivitis.

Keywords: bacterial conjunctivitis; levofloxacin; fluoroquinolone, Quixin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ferrer, C, Rodriguez, A, Abad, J L, Fernandez, J, Alio, J L (2008). Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis. Br. J. Ophthalmol. 92: 678-682 [Abstract] [Full Text]  
• Cantor, L B, WuDunn, D, Yung, C W, Valluri, S, Catoira, Y P, Hoop, J S, Morgan, L S (2008). Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. Br. J. Ophthalmol. 92: 345-347 [Abstract] [Full Text]  
• Protzko, E., Bowman, L., Abelson, M., Shapiro, A., for the AzaSite Clinical Study Group, (2007). Phase 3 Safety Comparisons for 1.0% Azithromycin in Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye Drops for Bacterial Conjunctivitis. IOVS 48: 3425-3429 [Abstract] [Full Text]  
• Ta, C. N. (2007). Topical Antibiotic Prophylaxis in Intraocular Injections. Arch Ophthalmol 125: 972-974 [Full Text]  
• Cochereau, I., Meddeb-Ouertani, A., Khairallah, M., Amraoui, A., Zaghloul, K., Pop, M., Delval, L., Pouliquen, P., Tandon, R., Garg, P., Goldschmidt, P., Bourcier, T. (2007). 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br. J. Ophthalmol. 91: 465-469 [Abstract] [Full Text]  
• Elizabeth Harkless, G. (2006). Topical chloramphenicol was not effective for acute infective conjunctivitis in children. Evid. Based Nurs. 9: 12-12 [Full Text]